Copenhagen Fights Last Pockets of Fire that Destroyed 400-year-old Landmark

Emergency management work in the former Stock Exchange of Copenhagen, Boersen, Wednesday, April 17, 2024. (Liselotte Sabroe/Ritzau Scanpix via AP)
Emergency management work in the former Stock Exchange of Copenhagen, Boersen, Wednesday, April 17, 2024. (Liselotte Sabroe/Ritzau Scanpix via AP)
TT

Copenhagen Fights Last Pockets of Fire that Destroyed 400-year-old Landmark

Emergency management work in the former Stock Exchange of Copenhagen, Boersen, Wednesday, April 17, 2024. (Liselotte Sabroe/Ritzau Scanpix via AP)
Emergency management work in the former Stock Exchange of Copenhagen, Boersen, Wednesday, April 17, 2024. (Liselotte Sabroe/Ritzau Scanpix via AP)

Danish firefighters were still at work extinguishing the last pockets of a fire that destroyed a 400-year-old Copenhagen landmark a day after the blaze began, The Associated Press reported Wednesday.

Morten Langager, manager of the Danish Chamber of Commerce, which was headquartered in the Old Stock Exchange and owned the building, said the building, built in 1615 and known for its green copper roof and distinctive 56-meter spire in the shape of four intertwined dragon tails, should “rise again.”

No decision has yet been made about whether the city will reconstruct the building, which would cost millions, if not billions of kroner (dollars).

Many in Denmark compared Tuesday’s fire to the April 2019 blaze at Notre Dame that destroyed the 800-year-old cathedral’s spire. Its restoration is slated for completion this year.

The head of the Danish Chamber of Commerce, Brian Mikkelsen, told Danish media that most of the building's most valuable contents had been saved. The building contained priceless paintings and other works of art, AP reported.

When the fire engulfed the building on Tuesday, passers-by, Chamber of Commerce staff, police officers and members of an army unit that had been sent to help raced inside the building to save its treasures.

The extent of the damage, caused by flames and the tons of water poured to extinguish them, was still unknown, as was the cause of the fire, which is believed to have started on the building's roof during renovations on Tuesday morning.

Huge billows of smoke rose over downtown Copenhagen and could be seen from southern Sweden, which is separated from the Danish capital by a narrow waterway. Ambulances were at the scene but there were no reports of casualties.

Smoke damage closed ministries located in the street behind the Old Stock Exchange, which remained shut Wednesday as employees were told to work from home because of a strong smell of smoke in the buildings.

The buildings must be thoroughly cleaned and their ventilation systems must be checked and perhaps replaced before ministry staff can return, said Rasmus Brandt Lassen, head of the Danish Building and Property Agency.

“We have told them that they should expect to work at home for the rest of the week,” Brandt Lassen said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”